Omestad (Omeprazole)

Omeprazole, the active ingredient in Omestad, is a proton pump inhibitor presented as a 20 mg tablet for oral use. It reduces stomach acid production and is used to manage gastro‑intestinal reflux disease and related conditions in adults. GNH USA supplies Omestad as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole acts on the gastric acid secretion pathway and is indicated for several acid‑related disorders. - Gastro‑esophageal reflux disease (GERD): provides symptomatic relief and promotes healing of erosive esophagitis. - Peptic ulcer disease: supports ulcer healing and reduces risk of recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with the condition.

Adverse reactions to omeprazole are generally mild to moderate, but serious events can occur.

Common Side Effects: - Headache: mild and transient. - Diarrhea: watery stools without blood. - Nausea: occasional feeling of stomach upset. - Abdominal pain: mild cramping or discomfort. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis presenting with watery diarrhea. - Acute interstitial nephritis: kidney inflammation with reduced urine output. - Stevens‑Johnson syndrome: severe skin rash with mucosal involvement. - Hepatic injury: elevated liver enzymes or jaundice. - Hypomagnesemia: low serum magnesium causing muscle cramps or arrhythmia. - Fracture risk: increased incidence of hip, wrist or spine fractures with long‑term use.

When prescribing omeprazole, clinicians should consider several safety aspects. - Assess renal and hepatic function: adjust use in severe impairment. - Review concomitant medications: potential for altered drug levels. - Monitor for infection: prolonged acid suppression may increase gastrointestinal infection risk. - Evaluate long‑term use: consider bone health and nutrient absorption. - Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment. - Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Omeprazole may affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, increasing cardiovascular event risk. - Atazanavir: decreased antiviral exposure, compromising HIV therapy. - Dasatinib: lower plasma concentrations, reducing oncologic efficacy.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR, requiring more frequent monitoring. - Phenytoin: decreased serum levels, possibly reducing seizure control. - Ketoconazole: reduced absorption, diminishing antifungal effectiveness.